ES2993669T3 - Human-derived bacteria that induce proliferation or accumulation of regulatory t cells - Google Patents

Info

Publication number

ES2993669T3

ES2993669T3 ES21198256T ES21198256T ES2993669T3 ES 2993669 T3 ES2993669 T3 ES 2993669T3 ES 21198256 T ES21198256 T ES 21198256T ES 21198256 T ES21198256 T ES 21198256T ES 2993669 T3 ES2993669 T3 ES 2993669T3

Authority

ES

Spain

Prior art keywords

mice

cells

clostridium

composition

regulatory

Prior art date

2011-12-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 190
• 238000009825 accumulation Methods 0.000 title claims abstract description 84
• 230000035755 proliferation Effects 0.000 title claims description 56
• 241000894006 Bacteria Species 0.000 title abstract description 102
• 241000282414 Homo sapiens Species 0.000 title abstract description 77
• 230000001580 bacterial effect Effects 0.000 claims abstract description 159
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
• 239000000203 mixture Substances 0.000 claims description 250
• 238000011282 treatment Methods 0.000 claims description 57
• 238000000034 method Methods 0.000 claims description 40
• 230000001939 inductive effect Effects 0.000 claims description 20
• 239000003795 chemical substances by application Substances 0.000 claims description 18
• 230000001506 immunosuppresive effect Effects 0.000 claims description 17
• 229960005486 vaccine Drugs 0.000 claims description 15
• 208000026935 allergic disease Diseases 0.000 claims description 14
• 239000000126 substance Substances 0.000 claims description 12
• 239000003814 drug Substances 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 11
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 11
• 229960004963 mesalazine Drugs 0.000 claims description 11
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
• 208000035473 Communicable disease Diseases 0.000 claims description 10
• 230000001078 anti-cholinergic effect Effects 0.000 claims description 10
• 208000015181 infectious disease Diseases 0.000 claims description 10
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 10
• 230000009467 reduction Effects 0.000 claims description 9
• 108091023040 Transcription factor Proteins 0.000 claims description 8
• 102000040945 Transcription factor Human genes 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 7
• 230000002265 prevention Effects 0.000 claims description 7
• 239000003381 stabilizer Substances 0.000 claims description 7
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 7
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 6
• 239000003246 corticosteroid Substances 0.000 claims description 6
• 229960001334 corticosteroids Drugs 0.000 claims description 6
• 239000003862 glucocorticoid Substances 0.000 claims description 6
• 229960001940 sulfasalazine Drugs 0.000 claims description 6
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 6
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 5
• 229930182837 (R)-adrenaline Natural products 0.000 claims description 5
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
• 229930105110 Cyclosporin A Natural products 0.000 claims description 5
• 108010036949 Cyclosporine Proteins 0.000 claims description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
• 230000002590 anti-leukotriene effect Effects 0.000 claims description 5
• 229940125715 antihistaminic agent Drugs 0.000 claims description 5
• 239000000739 antihistaminic agent Substances 0.000 claims description 5
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 5
• 239000011248 coating agent Substances 0.000 claims description 5
• 229960000265 cromoglicic acid Drugs 0.000 claims description 5
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 5
• 239000000850 decongestant Substances 0.000 claims description 5
• 229940124581 decongestants Drugs 0.000 claims description 5
• 229960005139 epinephrine Drugs 0.000 claims description 5
• 210000003630 histaminocyte Anatomy 0.000 claims description 5
• 239000003018 immunosuppressive agent Substances 0.000 claims description 5
• 229940124589 immunosuppressive drug Drugs 0.000 claims description 5
• 239000000463 material Substances 0.000 claims description 5
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 5
• 229960001428 mercaptopurine Drugs 0.000 claims description 5
• 229960000485 methotrexate Drugs 0.000 claims description 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
• 229960004618 prednisone Drugs 0.000 claims description 5
• 238000011321 prophylaxis Methods 0.000 claims description 5
• 206010039083 rhinitis Diseases 0.000 claims description 5
• 239000002904 solvent Substances 0.000 claims description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 5
• 229960000278 theophylline Drugs 0.000 claims description 5
• ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 4
• 239000000796 flavoring agent Substances 0.000 claims description 4
• 239000012138 yeast extract Substances 0.000 claims description 4
• 244000144725 Amygdalus communis Species 0.000 claims description 3
• 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
• 229920000945 Amylopectin Polymers 0.000 claims description 3
• 235000016068 Berberis vulgaris Nutrition 0.000 claims description 3
• 241000335053 Beta vulgaris Species 0.000 claims description 3
• 229920002488 Hemicellulose Polymers 0.000 claims description 3
• 229920001202 Inulin Polymers 0.000 claims description 3
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
• 229920000294 Resistant starch Polymers 0.000 claims description 3
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
• 235000020224 almond Nutrition 0.000 claims description 3
• 229960002685 biotin Drugs 0.000 claims description 3
• 235000020958 biotin Nutrition 0.000 claims description 3
• 239000011616 biotin Substances 0.000 claims description 3
• 239000003085 diluting agent Substances 0.000 claims description 3
• JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
• 229940029339 inulin Drugs 0.000 claims description 3
• JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
• 229960000511 lactulose Drugs 0.000 claims description 3
• PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
• 235000013379 molasses Nutrition 0.000 claims description 3
• 239000001814 pectin Substances 0.000 claims description 3
• 229920001277 pectin Polymers 0.000 claims description 3
• 235000010987 pectin Nutrition 0.000 claims description 3
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
• 235000021254 resistant starch Nutrition 0.000 claims description 3
• 239000008223 sterile water Substances 0.000 claims description 3
• 150000001491 aromatic compounds Chemical class 0.000 claims description 2
• 239000011230 binding agent Substances 0.000 claims description 2
• 239000006172 buffering agent Substances 0.000 claims description 2
• 239000003086 colorant Substances 0.000 claims description 2
• 239000003995 emulsifying agent Substances 0.000 claims description 2
• 239000000945 filler Substances 0.000 claims description 2
• 235000019634 flavors Nutrition 0.000 claims description 2
• 235000013355 food flavoring agent Nutrition 0.000 claims description 2
• 235000003599 food sweetener Nutrition 0.000 claims description 2
• 239000000314 lubricant Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 239000002504 physiological saline solution Substances 0.000 claims description 2
• 239000003755 preservative agent Substances 0.000 claims description 2
• 230000002335 preservative effect Effects 0.000 claims description 2
• 239000004094 surface-active agent Substances 0.000 claims description 2
• 239000000375 suspending agent Substances 0.000 claims description 2
• 239000003765 sweetening agent Substances 0.000 claims description 2
• 239000002562 thickening agent Substances 0.000 claims description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
• 239000008158 vegetable oil Substances 0.000 claims description 2
• 239000003981 vehicle Substances 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 210000001072 colon Anatomy 0.000 abstract description 101
• 241000894007 species Species 0.000 abstract description 91
• 241001112696 Clostridia Species 0.000 abstract description 27
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
• 201000010099 disease Diseases 0.000 abstract description 23
• 230000036737 immune function Effects 0.000 abstract description 10
• 230000001404 mediated effect Effects 0.000 abstract description 4
• 238000013519 translation Methods 0.000 abstract description 2
• 241000699670 Mus sp. Species 0.000 description 338
• 210000004027 cell Anatomy 0.000 description 150
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 102
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 96
• 230000035508 accumulation Effects 0.000 description 79
• 210000004400 mucous membrane Anatomy 0.000 description 69
• 230000014509 gene expression Effects 0.000 description 66
• 241000193403 Clostridium Species 0.000 description 63
• 239000000523 sample Substances 0.000 description 46
• 241000545067 Venus Species 0.000 description 41
• 210000000813 small intestine Anatomy 0.000 description 41
• YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 40
• 241000699666 Mus <mouse, genus> Species 0.000 description 40
• 230000002550 fecal effect Effects 0.000 description 40
• 235000013305 food Nutrition 0.000 description 36
• 210000003608 fece Anatomy 0.000 description 35
• 210000004698 lymphocyte Anatomy 0.000 description 33
• 230000000694 effects Effects 0.000 description 32
• 230000006698 induction Effects 0.000 description 32
• 230000000112 colonic effect Effects 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 30
• 108020004465 16S ribosomal RNA Proteins 0.000 description 27
• 239000003242 anti bacterial agent Substances 0.000 description 27
• 108090000623 proteins and genes Proteins 0.000 description 26
• 235000013361 beverage Nutrition 0.000 description 25
• 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 description 22
• 102100037796 Zinc finger protein Helios Human genes 0.000 description 22
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
• 239000002953 phosphate buffered saline Substances 0.000 description 22
• 239000000725 suspension Substances 0.000 description 22
• 210000001744 T-lymphocyte Anatomy 0.000 description 21
• 229940088710 antibiotic agent Drugs 0.000 description 21
• 239000000047 product Substances 0.000 description 20
• 241000193464 Clostridium sp. Species 0.000 description 19
• 210000005206 intestinal lamina propria Anatomy 0.000 description 19
• 229920001817 Agar Polymers 0.000 description 18
• 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 18
• 239000008272 agar Substances 0.000 description 18
• 210000001035 gastrointestinal tract Anatomy 0.000 description 18
• 238000000684 flow cytometry Methods 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 16
• 241001134569 Flavonifractor plautii Species 0.000 description 16
• 241000685809 [Clostridium] saccharogumia Species 0.000 description 16
• 239000012228 culture supernatant Substances 0.000 description 16
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
• 230000003115 biocidal effect Effects 0.000 description 15
• 230000037396 body weight Effects 0.000 description 15
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 15
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 14
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 14
• 206010009887 colitis Diseases 0.000 description 14
• 239000000306 component Substances 0.000 description 14
• 238000011081 inoculation Methods 0.000 description 14
• 230000000968 intestinal effect Effects 0.000 description 14
• 238000003753 real-time PCR Methods 0.000 description 14
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 14
• 241001147801 [Clostridium] scindens Species 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 241000193450 [Clostridium] symbiosum Species 0.000 description 12
• 238000001574 biopsy Methods 0.000 description 12
• 238000011740 C57BL/6 mouse Methods 0.000 description 11
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 11
• 208000019693 Lung disease Diseases 0.000 description 11
• 108010058846 Ovalbumin Proteins 0.000 description 11
• -1 acetyl-Co A Chemical compound 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 229940092253 ovalbumin Drugs 0.000 description 11
• 210000001986 peyer's patch Anatomy 0.000 description 11
• 206010012735 Diarrhoea Diseases 0.000 description 10
• 241001674997 Hungatella hathewayi Species 0.000 description 10
• 241001112693 Lachnospiraceae Species 0.000 description 10
• 241000736262 Microbiota Species 0.000 description 10
• 241000985249 [Clostridium] indolis Species 0.000 description 10
• 241001098250 [Clostridium] lavalense Species 0.000 description 10
• 244000005709 gut microbiome Species 0.000 description 10
• 238000002955 isolation Methods 0.000 description 10
• 210000001165 lymph node Anatomy 0.000 description 10
• 239000000825 pharmaceutical preparation Substances 0.000 description 10
• 235000013406 prebiotics Nutrition 0.000 description 10
• 238000012163 sequencing technique Methods 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 238000011870 unpaired t-test Methods 0.000 description 10
• 241000428313 Anaerotruncus colihominis Species 0.000 description 9
• 206010009900 Colitis ulcerative Diseases 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 102000013691 Interleukin-17 Human genes 0.000 description 9
• 108050003558 Interleukin-17 Proteins 0.000 description 9
• 201000006704 Ulcerative Colitis Diseases 0.000 description 9
• 241001246487 [Clostridium] bolteae Species 0.000 description 9
• 230000003834 intracellular effect Effects 0.000 description 9
• 210000000056 organ Anatomy 0.000 description 9
• 238000010186 staining Methods 0.000 description 9
• SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 8
• 241001148536 Bacteroides sp. Species 0.000 description 8
• 241000227342 Candidatus Arthromitus sp. SFB-mouse Species 0.000 description 8
• 241001531274 Faecalicatena contorta Species 0.000 description 8
• 208000029523 Interstitial Lung disease Diseases 0.000 description 8
• 241001464895 Lachnospiraceae bacterium DJF_VP30 Species 0.000 description 8
• 241001613662 Ruminococcus sp. ID8 Species 0.000 description 8
• 238000000692 Student's t-test Methods 0.000 description 8
• WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 8
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
• 230000002496 gastric effect Effects 0.000 description 8
• 210000000987 immune system Anatomy 0.000 description 8
• 230000036039 immunity Effects 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 244000052769 pathogen Species 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 229920002554 vinyl polymer Polymers 0.000 description 8
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 7
• 241000606125 Bacteroides Species 0.000 description 7
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 102100037850 Interferon gamma Human genes 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 241000263847 Lachnospiraceae bacterium 5_1_57FAA Species 0.000 description 7
• 241000186660 Lactobacillus Species 0.000 description 7
• 108010059993 Vancomycin Proteins 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 229920003045 dextran sodium sulfate Polymers 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 7
• 210000002602 induced regulatory T cell Anatomy 0.000 description 7
• 229940039696 lactobacillus Drugs 0.000 description 7
• 230000001717 pathogenic effect Effects 0.000 description 7
• 229920000642 polymer Polymers 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 238000002054 transplantation Methods 0.000 description 7
• 229960003165 vancomycin Drugs 0.000 description 7
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 7
• MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 7
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
• 208000016261 weight loss Diseases 0.000 description 7
• 241000448677 Anaerotruncus colihominis DSM 17241 Species 0.000 description 6
• 241000828264 Clostridiales bacterium 1_7_47FAA Species 0.000 description 6
• 241001272309 Clostridium sp. 316002/08 Species 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 241000828262 Erysipelotrichaceae bacterium 2_2_44A Species 0.000 description 6
• 241000605980 Faecalibacterium prausnitzii Species 0.000 description 6
• 241000192125 Firmicutes Species 0.000 description 6
• 239000012981 Hank's balanced salt solution Substances 0.000 description 6
• 208000032843 Hemorrhage Diseases 0.000 description 6
• 241001177766 Lachnospiraceae bacterium 2_1_46FAA Species 0.000 description 6
• 241000263846 Lachnospiraceae bacterium 3_1_57FAA_CT1 Species 0.000 description 6
• 241000263845 Lachnospiraceae bacterium 6_1_63FAA Species 0.000 description 6
• 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 6
• 241000962959 Pseudoflavonifractor capillosus ATCC 29799 Species 0.000 description 6
• 241000741965 [Clostridium] asparagiforme DSM 15981 Species 0.000 description 6
• 241000961103 [Clostridium] bolteae ATCC BAA-613 Species 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 230000003321 amplification Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 6
• 244000005700 microbiome Species 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 230000003393 splenic effect Effects 0.000 description 6
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 5
• 241000963043 Anaerostipes caccae DSM 14662 Species 0.000 description 5
• 101100518558 Arabidopsis thaliana OTU9 gene Proteins 0.000 description 5
• 108020000946 Bacterial DNA Proteins 0.000 description 5
• 241000522109 Clostridium sp. D5 Species 0.000 description 5
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 206010062016 Immunosuppression Diseases 0.000 description 5
• 102000004388 Interleukin-4 Human genes 0.000 description 5
• 108090000978 Interleukin-4 Proteins 0.000 description 5
• 229930193140 Neomycin Natural products 0.000 description 5
• 241001177797 [Clostridium] symbiosum WAL-14163 Species 0.000 description 5
• 230000007815 allergy Effects 0.000 description 5
• 241000318287 cf. Clostridium sp. MLG055 Species 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 235000009508 confectionery Nutrition 0.000 description 5
• 235000015872 dietary supplement Nutrition 0.000 description 5
• 210000003162 effector t lymphocyte Anatomy 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 230000037406 food intake Effects 0.000 description 5
• 238000003304 gavage Methods 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 229960004927 neomycin Drugs 0.000 description 5
• 230000002093 peripheral effect Effects 0.000 description 5
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 241001505572 Anaerostipes caccae Species 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241001208361 Bacteroides sp. MANG Species 0.000 description 4
• 241001202853 Blautia Species 0.000 description 4
• 241000186560 Blautia coccoides Species 0.000 description 4
• 108010008165 Etanercept Proteins 0.000 description 4
• 206010016946 Food allergy Diseases 0.000 description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
• 241001042460 Oscillibacter valericigenes Species 0.000 description 4
• 241001515661 Oscillospiraceae bacterium NML 061048 Species 0.000 description 4
• 210000000068 Th17 cell Anatomy 0.000 description 4
• 241001656794 [Clostridium] saccharolyticum Species 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 229960002964 adalimumab Drugs 0.000 description 4
• 229960000723 ampicillin Drugs 0.000 description 4
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
• 229960002170 azathioprine Drugs 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 229960003115 certolizumab pegol Drugs 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 239000012470 diluted sample Substances 0.000 description 4
• 229960000403 etanercept Drugs 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 229960001743 golimumab Drugs 0.000 description 4
• 230000013632 homeostatic process Effects 0.000 description 4
• 230000006058 immune tolerance Effects 0.000 description 4
• 229960000598 infliximab Drugs 0.000 description 4
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 229960000282 metronidazole Drugs 0.000 description 4
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 238000002255 vaccination Methods 0.000 description 4
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
• 241000186000 Bifidobacterium Species 0.000 description 3
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
• 241001430149 Clostridiaceae Species 0.000 description 3
• 241000193163 Clostridioides difficile Species 0.000 description 3
• 208000015943 Coeliac disease Diseases 0.000 description 3
• 102100027995 Collagenase 3 Human genes 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
• 235000010469 Glycine max Nutrition 0.000 description 3
• 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 3
• 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 3
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 3
• 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 3
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 3
• 206010030113 Oedema Diseases 0.000 description 3
• 241000134861 Ruminococcus sp. Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 210000000447 Th1 cell Anatomy 0.000 description 3
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 241000186569 [Clostridium] leptum Species 0.000 description 3
• 241000371060 [Clostridium] saccharolyticum WM1 Species 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 229940037003 alum Drugs 0.000 description 3
• 244000052616 bacterial pathogen Species 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 230000005587 bubbling Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 210000004970 cd4 cell Anatomy 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 208000018631 connective tissue disease Diseases 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 238000000855 fermentation Methods 0.000 description 3
• 230000004151 fermentation Effects 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 235000013402 health food Nutrition 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 3
• 210000005004 lymphoid follicle Anatomy 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000006041 probiotic Substances 0.000 description 3
• 235000018291 probiotics Nutrition 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 235000014347 soups Nutrition 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 210000001541 thymus gland Anatomy 0.000 description 3
• 229910052719 titanium Inorganic materials 0.000 description 3
• 239000010936 titanium Substances 0.000 description 3
• 235000013618 yogurt Nutrition 0.000 description 3
• WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
• 108091093088 Amplicon Proteins 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 2
• 208000036487 Arthropathies Diseases 0.000 description 2
• 241001674039 Bacteroides acidifaciens Species 0.000 description 2
• 241000605059 Bacteroidetes Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
• 229930186147 Cephalosporin Natural products 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 238000007399 DNA isolation Methods 0.000 description 2
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
• 241001109643 Faecalicatena fissicatena Species 0.000 description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 208000001204 Hashimoto Disease Diseases 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 241000862470 Holdemania filiformis Species 0.000 description 2
• 241001529428 Hydrogenoanaerobacterium saccharovorans Species 0.000 description 2
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
• 206010020850 Hyperthyroidism Diseases 0.000 description 2
• 101150085950 IL10 gene Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
• 208000012659 Joint disease Diseases 0.000 description 2
• 240000001046 Lactobacillus acidophilus Species 0.000 description 2
• 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 2
• 101150053046 MYD88 gene Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010061297 Mucosal erosion Diseases 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 201000011152 Pemphigus Diseases 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 108010093965 Polymyxin B Proteins 0.000 description 2
• 241000280572 Pseudoflavonifractor Species 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020001027 Ribosomal DNA Proteins 0.000 description 2
• 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 241000193458 [Clostridium] aminophilum Species 0.000 description 2
• 241000186561 [Clostridium] clostridioforme Species 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 229960005361 cefaclor Drugs 0.000 description 2
• QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
• 229960003012 cefamandole Drugs 0.000 description 2
• OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 2
• 229960002682 cefoxitin Drugs 0.000 description 2
• 229960002580 cefprozil Drugs 0.000 description 2
• 229960001668 cefuroxime Drugs 0.000 description 2
• JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 229940124587 cephalosporin Drugs 0.000 description 2
• 150000001780 cephalosporins Chemical class 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
• 235000013365 dairy product Nutrition 0.000 description 2
• 238000000354 decomposition reaction Methods 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 229920006237 degradable polymer Polymers 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 235000011850 desserts Nutrition 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 108010007093 dispase Proteins 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 201000000708 eosinophilic esophagitis Diseases 0.000 description 2
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 238000001125 extrusion Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000020932 food allergy Nutrition 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 235000013376 functional food Nutrition 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 244000005702 human microbiome Species 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000016507 interphase Effects 0.000 description 2
• 235000015110 jellies Nutrition 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 244000144972 livestock Species 0.000 description 2
• 230000007108 local immune response Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 235000011837 pasties Nutrition 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 108010089193 pattern recognition receptors Proteins 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
• 238000007747 plating Methods 0.000 description 2
• 229920000024 polymyxin B Polymers 0.000 description 2
• 229960005266 polymyxin b Drugs 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 230000000529 probiotic effect Effects 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000012175 pyrosequencing Methods 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 201000008827 tuberculosis Diseases 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
• IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
• 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 1
• VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 101150039504 6 gene Proteins 0.000 description 1
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
• 241000023308 Acca Species 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 206010059447 Allergic colitis Diseases 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 229920000310 Alpha glucan Polymers 0.000 description 1
• 244000208874 Althaea officinalis Species 0.000 description 1
• 235000006576 Althaea officinalis Nutrition 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
• 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
• 101100406673 Arabidopsis thaliana OTU3 gene Proteins 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 206010071155 Autoimmune arthritis Diseases 0.000 description 1
• 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 description 1
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000606124 Bacteroides fragilis Species 0.000 description 1
• 241000606215 Bacteroides vulgatus Species 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 241001608472 Bifidobacterium longum Species 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101150101767 Card9 gene Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 241000725101 Clea Species 0.000 description 1
• 241001112695 Clostridiales Species 0.000 description 1
• 208000037384 Clostridium Infections Diseases 0.000 description 1
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
• 206010054236 Clostridium difficile infection Diseases 0.000 description 1
• 241000886561 Clostridium sp. MLG055 Species 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• 206010013700 Drug hypersensitivity Diseases 0.000 description 1
• 208000027244 Dysbiosis Diseases 0.000 description 1
• 208000004739 Egg Hypersensitivity Diseases 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000006353 Filariasis Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
• 208000031856 Haemosiderosis Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
• 241001180747 Hottea Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 208000000038 Hypoparathyroidism Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 description 1
• 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 description 1
• 208000015580 Increased body weight Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 102100022297 Integrin alpha-X Human genes 0.000 description 1
• 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
• JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 239000004158 L-cystine Substances 0.000 description 1
• 235000019393 L-cystine Nutrition 0.000 description 1
• 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
• 241000186840 Lactobacillus fermentum Species 0.000 description 1
• 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
• 208000012309 Linear IgA disease Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
• 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
• 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
• 208000007466 Male Infertility Diseases 0.000 description 1
• 240000002129 Malva sylvestris Species 0.000 description 1
• 235000006770 Malva sylvestris Nutrition 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
• RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
• 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
• 201000010859 Milk allergy Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 101150106019 Mmp2 gene Proteins 0.000 description 1
• 101150035730 Mmp9 gene Proteins 0.000 description 1
• 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 101100109294 Mus musculus Arhgef28 gene Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 102000012064 NLR Proteins Human genes 0.000 description 1
• 108091005686 NOD-like receptors Proteins 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 208000002366 Nut Hypersensitivity Diseases 0.000 description 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 239000004100 Oxytetracycline Substances 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
• 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 229930195708 Penicillin V Natural products 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 235000006089 Phaseolus angularis Nutrition 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
• 208000002389 Pouchitis Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 238000011530 RNeasy Mini Kit Methods 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
• 206010067953 Radiation fibrosis Diseases 0.000 description 1
• KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
• 206010038063 Rectal haemorrhage Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010048908 Seasonal allergy Diseases 0.000 description 1
• 241000304405 Sedum burrito Species 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 206010062164 Seronegative arthritis Diseases 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 208000008555 Shellfish Hypersensitivity Diseases 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 241000271567 Struthioniformes Species 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 240000007098 Vigna angularis Species 0.000 description 1
• 235000010711 Vigna angularis Nutrition 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000006903 Wheat Hypersensitivity Diseases 0.000 description 1
• 229920002000 Xyloglucan Polymers 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 201000010272 acanthosis nigricans Diseases 0.000 description 1
• 208000018254 acute transverse myelitis Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 235000013334 alcoholic beverage Nutrition 0.000 description 1
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
• 229960003022 amoxicillin Drugs 0.000 description 1
• LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000027841 autoimmune hepatitis type 2 Diseases 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940062316 avelox Drugs 0.000 description 1
• 235000013405 beer Nutrition 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940009291 bifidobacterium longum Drugs 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 235000015895 biscuits Nutrition 0.000 description 1
• 208000002352 blister Diseases 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 235000008429 bread Nutrition 0.000 description 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
• 229960003669 carbenicillin Drugs 0.000 description 1
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 229960004841 cefadroxil Drugs 0.000 description 1
• NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
• 229960000603 cefalotin Drugs 0.000 description 1
• 229960001139 cefazolin Drugs 0.000 description 1
• MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
• 229960003719 cefdinir Drugs 0.000 description 1
• RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
• 229960004069 cefditoren Drugs 0.000 description 1
• KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
• 229960002129 cefixime Drugs 0.000 description 1
• 229960004682 cefoperazone Drugs 0.000 description 1
• GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
• 229960004261 cefotaxime Drugs 0.000 description 1
• AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
• 229960000484 ceftazidime Drugs 0.000 description 1
• NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
• 229960004086 ceftibuten Drugs 0.000 description 1
• SSWTVBYDDFPFAF-DKOGRLLHSA-N ceftibuten dihydrate Chemical compound O.O.S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 SSWTVBYDDFPFAF-DKOGRLLHSA-N 0.000 description 1
• 229960001991 ceftizoxime Drugs 0.000 description 1
• NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
• VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 description 1
• 229950004259 ceftobiprole Drugs 0.000 description 1
• 229960004755 ceftriaxone Drugs 0.000 description 1
• VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 229920003174 cellulose-based polymer Polymers 0.000 description 1
• 229940106164 cephalexin Drugs 0.000 description 1
• AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
• VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 235000013351 cheese Nutrition 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229940088516 cipro Drugs 0.000 description 1
• ARPUHYJMCVWYCZ-UHFFFAOYSA-N ciprofloxacin hydrochloride hydrate Chemical compound O.Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 ARPUHYJMCVWYCZ-UHFFFAOYSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 238000010411 cooking Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 201000005344 crustacean allergy Diseases 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 235000021438 curry Nutrition 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 235000019543 dairy drink Nutrition 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 108010025838 dectin 1 Proteins 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229960001585 dicloxacillin Drugs 0.000 description 1
• YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960000895 doripenem Drugs 0.000 description 1
• AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 230000007140 dysbiosis Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 201000010860 egg allergy Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229960002770 ertapenem Drugs 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 235000019985 fermented beverage Nutrition 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 229960000628 fidaxomicin Drugs 0.000 description 1
• ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229930003935 flavonoid Natural products 0.000 description 1
• 235000017173 flavonoids Nutrition 0.000 description 1
• 229940072686 floxin Drugs 0.000 description 1
• 229940124307 fluoroquinolone Drugs 0.000 description 1
• 235000012041 food component Nutrition 0.000 description 1
• 239000005428 food component Substances 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 235000020510 functional beverage Nutrition 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 210000003736 gastrointestinal content Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• 230000000273 goitrogenic effect Effects 0.000 description 1
• 235000011868 grain product Nutrition 0.000 description 1
• 235000001497 healthy food Nutrition 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 102000054350 human CHI3L1 Human genes 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 235000015243 ice cream Nutrition 0.000 description 1
• 210000002861 immature t-cell Anatomy 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 229940099472 immunoglobulin a Drugs 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000009655 industrial fermentation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 235000014109 instant soup Nutrition 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000031261 interleukin-10 production Effects 0.000 description 1
• 230000017307 interleukin-4 production Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 229940089519 levaquin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
• 229960003907 linezolid Drugs 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229960002260 meropenem Drugs 0.000 description 1
• CTUAQTBUVLKNDJ-OBZXMJSBSA-N meropenem trihydrate Chemical compound O.O.O.C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 CTUAQTBUVLKNDJ-OBZXMJSBSA-N 0.000 description 1
• 238000010197 meta-analysis Methods 0.000 description 1
• 229960003085 meticillin Drugs 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 235000012459 muffins Nutrition 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• 238000011392 neighbor-joining method Methods 0.000 description 1
• 229960000808 netilmicin Drugs 0.000 description 1
• ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
• 235000012149 noodles Nutrition 0.000 description 1
• 235000015816 nutrient absorption Nutrition 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229960000625 oxytetracycline Drugs 0.000 description 1
• IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
• 235000019366 oxytetracycline Nutrition 0.000 description 1
• LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
• 229960001914 paromomycin Drugs 0.000 description 1
• UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
• 235000015927 pasta Nutrition 0.000 description 1
• 238000009928 pasteurization Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 201000010853 peanut allergy Diseases 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940056367 penicillin v Drugs 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
• 235000021110 pickles Nutrition 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 201000004338 pollen allergy Diseases 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000013594 poultry meat Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 108010009004 proteose-peptone Proteins 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 229950003551 ramoplanin Drugs 0.000 description 1
• 108010076689 ramoplanin Proteins 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 235000021067 refined food Nutrition 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 235000015067 sauces Nutrition 0.000 description 1
• 235000013580 sausages Nutrition 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 235000014102 seafood Nutrition 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 201000004336 shellfish allergy Diseases 0.000 description 1
• 235000021391 short chain fatty acids Nutrition 0.000 description 1
• 150000004666 short chain fatty acids Chemical class 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000014214 soft drink Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000012414 sterilization procedure Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 235000013616 tea Nutrition 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 229940072172 tetracycline antibiotic Drugs 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000025366 tissue development Effects 0.000 description 1
• 150000003608 titanium Chemical class 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
• 230000023750 transforming growth factor beta production Effects 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 239000001974 tryptic soy broth Substances 0.000 description 1
• 108010050327 trypticase-soy broth Proteins 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229920006163 vinyl copolymer Polymers 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 201000006520 wheat allergy Diseases 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 235000020138 yakult Nutrition 0.000 description 1
• 108091005957 yellow fluorescent proteins Proteins 0.000 description 1